Analysis of normalized TCGA data revealed significant PELI1 upregulation across multiple malignancies, including cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma (KIRC), hepatocellular carcinoma (LIHC), and stomach adenocarcinoma (STAD) (Figure 1A, Supplementary Table S1). This evidence concerns the gene PELI1 and hepatocellular carcinoma.